CDK 4/6 Inhibitors: Evolution and Revolution in the Management of ER+ Metastatic Breast Cancer
- PMID: 34637353
- DOI: 10.1200/OP.21.00611
CDK 4/6 Inhibitors: Evolution and Revolution in the Management of ER+ Metastatic Breast Cancer
Conflict of interest statement
Comment on
-
Clinical Review on the Management of Hormone Receptor-Positive Metastatic Breast Cancer.JCO Oncol Pract. 2022 May;18(5):319-327. doi: 10.1200/OP.21.00384. Epub 2021 Oct 12. JCO Oncol Pract. 2022. PMID: 34637323 Review.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical